Synthetic ribozymes are catalytic RNA molecules designed to inhibit gene expression by cleaving specific mRNA sequences. We investigated the potential of synthetic ribozymes to inhibit bcl-2 expression in apoptosis defective bcl-2 overexpressing tumors. A chemically stabilized hammerhead ribozyme has been targeted to the A+U-rich regulative element of bcl-2 mRNA that is involved in bcl-2 gene switch-off during apoptosis. The design of the ribozyme was based on the results of probing accessibility of the RNA target in cellular extracts with antisense DNA. The ribozyme was lipotransfected to a bcl-2 overexpressing human lymphoma cell line (Raji). The cellular uptake of this ribozyme resulted in a marked reduction of both bcl-2 mRNA and BCL-2 protein levels and dramatically increased cellular death by apoptosis. Our results suggest a potential therapeutic application of such ribozyme for the treatment of bcl-2 overexpressing tumors.
R ibozymes are enzymes that bind and cleave RNA molecules in a sequence-specific manner. The ability of ribozymes to cleave RNA in an intermolecular (trans) mode allows one to design synthetic molecules with ability to cleave mRNAs in the specifically designated site, and thus to inhibit gene expression and analyze gene function. 1, 2 The trans-acting hammerhead ribozyme is the smallest RNA enzyme with endoribonuclease activity. 1 This ribozyme consists of three helical stems, including nine conserved nucleotides that are responsible for the formation of the catalytic domain. 1 The target site for the ribozyme can have any sequence as long as it contains UH, where H can be any nucleotide except G. The cleavage specificity of the ribozyme is determined by its hybridizing arms, which anneal to the target mRNA in a complementary fashion. Following binding, the ribozyme cleaves its mRNA target. After dissociation, the ribozyme is again capable of cleaving more mRNA molecules, thus fulfilling the definition of enzyme. 1, 2 Hence, besides the antisense effect, ribozymes hold an additional catalytic activity in contrast to antisense oligonucleotides that need the additional help of the RNaseH enzyme. 1 The specificity of this action at the level of gene expression makes ribozyme therapy a powerful tool with potential wide-range clinical application. The bcl-2 gene provides a rational target for ribozyme strategies. bcl-2 was originally detected at the breakpoint of the t(14;18)(q32;q21) chromosomal translocation 3 that typically occurs in human follicular B-cell lymphomas. 4 Juxtaposition of bcl-2 to the enhancer of immunoglobulin heavy chain (IgH) gene induces constitutive overexpression of bcl-2. 4 The bcl-2 gene product is a 25 kDa membrane protein that prevents cell apoptosis 5 and is also found at abnormally high levels in many human cancers, including breast, prostate, colorectal, lung, gastric and renal carcinomas, neuroblastoma, melanoma, acute and chronic leukemias. 6 As a consequence of Bcl-2 protein ability to inhibit apoptosis, bcl-2 overexpression is associated with tumor development or progression, and resistance to anticancer chemo-and radiotherapy. 6 bcl-2 is overexpressed in the majority of low-grade non-Hodgkin's lymphoma cases and approximately 50% of high-grade non-Hodgkin's lymphoma. 7 Inhibition of the expression of bcl-2 by antisense strategies, in some cancer cells, results in loss of their malignant behavior. In lymphoma cells, the blocking expression of bcl-2 by antisense molecules triggers apoptosis and enhances sensitivity to chemotherapeutic drugs. 8 bcl-2 expression is regulated at both the transcriptional and posttranscriptional level. We previously identified a mechanism of posttranscriptional regulation of bcl-2 expression that is mediated by an adenylate uridylate-rich element (A+U-rich element, ARE) of its mRNA.
AREs have been reported as cis-acting elements located in the 3 0 UTR of a wide variety of short-lived mRNAs like those of proto-oncogenes and cytokines. 10 They are endowed with a variable number of overlapping AUUUA pentamers, frequently harbored in or flanked to U-rich regions. Generally, inclusion of these sequences within 3 0 UTR of mRNAs accelerates their decay, but with different characteristics and extension of decay depending on individual ARE and cell type. The bcl-2 ARE possesses a moderate destabilizing activity that can be enhanced by apoptotic stimuli 9 and modifications of bcl-2 mRNA AU-binding protein. 11 The 3 0 UTR ARE region of mRNA plays a central role in the regulation of bcl-2 gene expression. Our strategy to downregulate bcl-2 expression exploits synthetic ribozymes targeting this region. Several factors that contribute to the intracellular efficacy of ribozymes have to be considered in their design. These factors include target site selection, ribozyme delivery, stability and intracellular localization. In contrast to ribozymes delivered endogenously via DNA vectors, exogenously delivered synthetic ribozymes offer the possibility for developing therapeutic agents that can be applied locally. The therapeutic utility of synthetic ribozymes is limited by their short half-life in vivo and limited accessibility to their RNA target. The 2 0 -hydroxyl group plays an important role in RNA degradation by nucleases; modification of this group can protect synthetic ribozymes against degradation. Several modifications, such as 2 0 -deoxyribonucleotide, 12 2 0 -O-methyl groups, 13 2 0 -fluoro-and 2 0 -amino groups, 14, 15 or 2 0 -deoxyribonucleotides together with phosphorothioate linkages, 16 have been since described and tested. The efficiency of the ribozyme reaction is principally dependent on the complementary arms flanking the catalytic core domain of the ribozyme and the target mRNA structure. 2 Despite computer programs predicting single-stranded or loop regions of the RNA substrate, the most effective cleavage sites of the target are found by experimental approaches. 2 We previously designed a synthetic ribozyme directed towards the bcl-2 mRNA AU-rich region. 17 In this report, by probing the local accessibility of ARE RNA by antisense ODN, we confirmed the accessibility of this site and, in consequence, we designed a synthetic 2 0 -modified hammerhead ribozyme targeting the bcl-2 ARE. This ribozyme strongly reduced both bcl-2 mRNA and BCL-2 protein levels in a bcl-2 overexpressing human lymphoma cell line (Raji) and committed these cells to apoptosis. These results indicate the potential therapeutic value of this ribozyme, and suggest that AREs could be optimal targets for synthetic ribozymes and, consequently, for therapeutic gene targeting.
Materials and methods

Cell line
The Raji (Burkitt lymphoma) cell line was maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, 50 IU/ml penicillin and 50 mg/ml streptomycin in a humidified atmosphere of 5% CO 2 at 371C. 
Reagents
Plasmids
The forward primer (ARE 3-Fw) 5
0 -atagggccc-ATGCAA-CATGCCTGCC-3 0 (flanked by the ApaI site) and the reverse primer (ARE 3-Rv) 5
0 -atacccgggGGT-GATCCGGCCAAC-3 0 (flanked by the Sma I site) were used to amplify by PCR the 396 bp UI segment containing the 3 0 -UTR ARE sequence from the template plasmid pBBB-U1. 3 This U1 segment was cloned in the pCR-II (Invitrogen Corporation) in order to produce the pCRU1 plasmid.
Ribozymes
Hammerhead modified ribozymes were chemically synthesized and PAGE purified by IBA (Gottingen, Germany) and resuspended in water. The homogeneity of the ribozyme was checked by analytical PAGE. RNA concentration was determined by assuming an extinction coefficient of 6.6 Â 103 cmÀ1 at 260 nm. The sequences of the ribozymes designed to target the bcl-2 ARE RNA (ARE-ribozymes) were 5 0 -AUAGCUCUGAU-GAGGCCGAAAGGCCGAAAUUCGAC-3 0 (active non-modified) and 5 0 -A*UAGCUCUGAUGAGGCC-GAAAGGCCGAAAUUC*G*A*C-3 0 (active modified). Asterisks indicate terminal phosphorothioate, and bold indicates U4 and U7 2 0 -aminouridines. All pyrimidine nucleotides are 2 0 -fluoro-deoxypyrimidine nucleotides. Structures of the hammerhead ribozyme are shown in Figure 1A . An inactive ribozyme (5 0 -A*UAGCU-CUAAUGAGGCCGAAAGGCCGAUAUUC*G*A*C-3 0 ) with the binding arm sequences of the parental ribozyme preserved, and thus still capable to bind the mRNA target, but with two nucleotide changes inserted in the core cleavage sequence was also tested. A modified inverted ribozyme (5 0 -U*CGAUACUGAUGAGGCC-GAAAGGCCGAAAUCA*G*C*U-3 0 ) containing the core sequence of the hammerhead active ribozyme but with inverted sequences of the binding arms was used as control for sequence specificity of the inhibitory effect (inverted control).
In vitro transcription
Transcription of plasmid pCRU1 (containing the bcl-2 mRNA ARE from nucleotides 752 to 1147) to generate a bcl-2 ARE RNA substrate of 395 nucleotides was carried out as described. 15 Cleavage kinetics with ARE RNA
The k cat and KM values were determined under single turnover conditions. 15 Kinetic constants for the cleavage were obtained by plotting the observed cleavage rate, k obs , against the quotient of k obs over the ribozyme concentration [E]g, according to the following equation:
The reaction rate kobs equals the negative logarithm of the remaining substrate (FracS) divided by the reaction time t. The negative slope represents the K M value, and the intercept of the regression line with the ordinate gives the maximal reaction rate, k react , under single turnover conditions.
14 Data were fitted to the Michaelis-Menten equation by KaleidaGraph (Synergy Software, Reading, PA).
Lipotransfection experiments
The day before the lipotransfection, exponentially growing Raji cells were seeded at a density of 2 Â 105 cells/well of a 24-well plate. The transfection mixtures were prepared by mixing DOTAP in serum-and antibioticsfree RPMI 1640 medium with the active or inactive AREribozyme or the inverted control. DOTAP/ribozyme complexes were allowed to form at room temperature for 20 min before the treatment of cells. The volumes of the DOTAP-vehiculated ribozyme or control mixtures were 20 ml per 200 ml of medium/well. The final concentration of each ribozyme was 2 mM and 25 mg/ml of DOTAP. After 6 h, 200 ml of RPMI 1640 supplemented with 10% FCS, 2 mM glutamine, 50 IU/ml penicillin and 50 mg/ml streptomycin was added. Lipotransfected cells were cultured for an additional 48 h.
Accessibility of antisense oligodeoxynucleotides (ASOs)
Raji cell extracts were incubated with 1 mM DTT, RNasin and 50 nM of each ASO for 5 min at 371C. The mixtures were digested with 10 ml of Dnase I (10 U/ml) for 1 h at 371C, followed by phenol extraction and ethanol precipitation. The precipitates were resuspended in 10 ml of DEPC water.
RNA mixtures were reverse transcribed and amplified by using the ''RT-PCR System kit'' (Promega, WI) according to the protocol recommended by the manufacturer. The amplification conditions were: denaturation at 941C for 2 min, annealing at 581C for 1 min, extension at 721C for 2 min, by performing 25 cycles in the presence of 1 ml of a-32 deoxycytidine triphosphate (3000 Ci/mmol, Amersham) in a 50 ml final volume. The 148 bp PCR was obtained with the sense (5 0 -GGACAACATCGCCCTGTG-3 0 ) and antisense (5 0 -AGTCTTCAGAGACAGCCAGGA-3 0 ) primers of bcl-2. The sense (5 0 -CCATGGGAAATCG-TGCGTGACATTA-3 0 ) and antisense (5 0 -GGGCCCA-ATGGTGATGACCTGGCCG-3 0 ) primers of b-actin, used as internal standard, resulted in 144 bp PCR product.
The PCR products were analysed by electrophoresis on an 8% denaturing polyacrylamide gel. Radioactive PCR products were quantitated using a Storm PhosphorImager and Image QuaNT software (Molecular Dynamics).
RT-PCR analysis of bcl-2 mRNA
The levels of bcl-2 mRNA were determined by a semiquantitative RT-PCR protocol described previously 18 using a Storm PhosphorImager and Image QuaNT software (Molecular Dynamics). Briefly, total RNA was isolated from Raji cells lipotransfected with the active or inactive ARE-ribozymes or the inverted control. For each treatment, 1 mg of total RNA was reverse transcribed using random hexamers and different volumes of the RT products were amplified by PCR. The amplification conditions were: denaturation at 941C for 2 min, annealing at 581C for 1 min, extension at 721C for 2 min for 35 cycles in a 50 ml final volume. The PCR products were analyzed by an 2% agarose gel. The sense (5 0 -GGACAACATCGCCCTGTG-3 0 ) and antisense (5 0 -AGTCTTCAGAGACAGCCAGGA-3 0 ) primers of bcl-2 led to a 148 bp PCR product. The sense (5 0 -CCATGG-GAAATCGTGCGTGACATTA-3 0 ) and antisense (5 0 -GGGCCCAATGGTGATGACCTGGCCG-3 0 ) primers of b-actin, used as internal standard, resulted in 144 bp PCR product.
Western blot analysis of Bcl-2 protein levels
Cells were transfected as above; controls and ribozymetreated cells were harvested, and washed with PBS before lysing them. Cell extracts were prepared by lysis in Nonidet P-40 lysis buffer (25 mM Tris, pH 7.5, 100 mM KCl, 0.25 mM dithioerythritol, 10 mM MgCl 2 , 1% Nonidet p40, protease inhibitor) for 30 min on ice. After centrifugation for 15 min at 12 000 Â g, supernatants were frozen. Protein concentration was determined using the BCA reagent following the manufacturer's protocol. Proteins (15 mg) were separated on 12.5% SDS-PAGE and electrotransferred (Trans-blot Semi-Dry-Biorad) to nitrocellulose transfer membrane. Bcl-2 and tubulin proteins were detected with primary antibodies using a 1 : 1000 dilution of mouse monoclonal anti-Bcl-2 antibody (Santa Cruz Biotechnology Inc.) and a 1 : 100 dilution of antitubulin antibody (Calbiochem), respectively. Blots were developed using horseradish peroxidase-conjugated goat anti-rabbit antibodies (1 : 1500) as secondary antibody. Protein bands were visualized using ECL detection reagent according to the protocol (Amersham) and quantified by using 'NIH image 1.62' software.
Evaluation of living cells and apoptotic events by time-lapse videomicroscopy
The number of living cells was estimated by the trypan blue exclusion test. Apoptotic cells were identified by time-lapse videomicroscopy using a Zeiss inverted phasecontrast microscope equipped with a Â 10 objective, Panasonic CCD cameras and JVC BR9030 time-lapse video recorders. The apoptotic events were scored the moment the cell became fully shrunk and split in the apoptotic bodies.
Results
Design and activity in vitro of the ARE-ribozyme
The successful disruption of gene expression depends on the identification of target RNA regions that contain cleavage sites accessible for ribozyme-substrate complex formation. This is because of differing local target accessibilities, which are a consequence of complex secondary and tertiary intermolecular folding. The human bcl-2 ARE contains several potential cleavage sites. Firstly, we searched for sites outside of RNA stretches with a high degree of secondary structures. The simulated folding of bcl-2 ARE by the MUFOLD program 19 showed some single-strand ''open'' regions with potential binding access for our ribozyme. In the living cells, however, RNA structure and, thus, accessibility are dependent on the intracellular environment. So, to evaluate the accessibility of target sequences for antisense base pairing, we used endogenous RNaseH activity present in the extracts prepared from Raji cells by ASO binding to native target ARE RNA (see Materials and methods). We examined three potential ribozyme cleavage sites in the ARE RNA using antisense DNA targeted to endogenous ARE RNA in extracts prepared from Raji cells. Each antisense DNA flanked a potential NUH 0 (N ¼ any base, H ¼ A, c, or U) cleavage site for hammerhead ribozyme. RNaseH selectively degrades RNA in RNA/DNA hybrids and the amount of cleavage is directly proportional to accessibility of the antisense DNA to the base pair. The reduction of substrate was evaluated by RT-PCR using primers that flank the ARE region chosen for site selection. Quantitation of the target RNA reduction was performed by analysis of the amplified target RNA versus amplification of a nontargeted internal standard, endogenous b-actin mRNA. Results from these analyses are summarized in Table 1 . The greatest reduction (45%) was obtained by antisense DNA #3. In contrast, antisense DNA#1 and #2 showed a very poor reduction ( Table 1) . Correlation of these data with computer-aided selection indicated the AUC site at position 944 as the best target site for the bcl-2 AREtargeting ribozyme (ARE-ribozyme) (Fig 1) as previously seen. 17 This site falls in the ARE region not conserved in all ARE-coding mRNAs, outside of the pentameric (AUUUA) sequence, and was demonstrated to be highly specific by search for homology in the human genome database. We chemically synthesized a specific AUC hammerhead ribozyme (ARE-ribozyme) and employed under single-turnover conditions in the cleavage reaction to check its cleavage efficiency ( Table 2 ). The incubation of the ARE-ribozyme with the full-length synthetic bcl-2 ARE in vitro transcript of 396 bases resulted in the expected cleavage products of 202 and 194 bases that migrated as a single band (data not shown).
Molecular activity of the modified ARE-ribozyme in Burkitt lymphoma cells
Cellular lipotransfection with the unmodified AREribozyme resulted in its rapid degradation owing to its low stability within the cell, and was confirmed by PAGE analysis of total RNA extracted from Raji cells following lipotransfection with the radiolabelled ribozyme (data not shown). Reaction conditions were as described under 'Materials and methods'. The measurements were repeated three times. M, modified ribozyme.
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The ribozymes with modifications at the 2 0 -position of pyrimidine nucleotides and phosphorothioates at the termini were used 14, 15 to protect against nucleases and to extend their stability. The nonmodified ribozyme was also used to determine its catalytic activity and to compare it with that of the modified ribozyme. The catalytic activities of the nonmodified and modified ribozymes were comparable (Table 2) . To examine the cleavage activity in cells, Burkitt lymphoma Raji cells were transiently lipotransfected with three modified AREribozymes. A catalytically inactive modified ARE-ribozyme containing two mutations in the catalytic core (G5A and A14G) leading to complete abolishment of cleavage capacity, and a ribozyme containing an active catalytic domain but with inverted sequences of the binding arms (inverted control) were used as controls. Ribozyme with inverted arms served as a control for the sequence-specific effect of the active ribozyme. At the concentration used, no apparent cytotoxicity of DOTAP was detected on Raji cell survival as assessed by a trypan blue exclusion test (data not shown). The total RNA was extracted 48 h after lipotransfection, and quantitated by RT-PCR as previously reported, 19 with specific primers for bcl-2. The bactin cDNA was used as internal standard. Serial dilutions of cDNA were amplified by 35 cycles of PCR. The amplification products were quantitated by densitometric analysis. Within the linear range of amplification, at least three values of PCR products relative to bcl-2 mRNA were normalized to starting cDNA volumes, and referred to the values of PCR products relative to b-actin mRNA. The analysis of cDNA products from modified active ribozyme-treated cells was compared with that from controls: modified inactive ARE-ribozyme and inverted control-treated cells by normalizing to b-actin (Fig 2a) . The active form of the modified ARE-ribozyme reduced by at least five-fold the amount of bcl-2 mRNA with respect to the inverted control, while the inactive form of ARE-ribozyme elicited a very scarce effect on this parameter. This indicated both the specificity of bcl-2 mRNA cellular cleavage by the modified ARE-ribozyme and its catalytic activity.
The effect of the modified active ARE-ribozyme on the cellular levels of BCL-2 protein evaluated by Western blot analysis and quantitated by densitometric analysis is shown in Fig 2b. At 48 h after administration of the active modified ARE-ribozyme, the amount of BCL-2 protein decreased by two-thirds (Fig 2b, lane 1) as compared to that obtained with the inactive ARE-ribozyme and the inverted control (Fig 2b, lanes 2 and 3) . These results clearly indicate that the modified ARE-ribozyme was able to downregulate specifically the expression of bcl-2 mRNA in Raji Burkitt lymphoma cells as well as the expression of the antiapoptotic Bcl-2 protein.
Western blot was probed with antitubulin antibody as the control for cell extract loading.
Effect of ARE-ribozyme on induction of apoptosis
In order to evaluate the phenotypic effects of bcl-2 downregulation elicited by active modified ARE-ribo- Downregulation of bcl-2 expression E Luzi et al zyme and the control modified ribozymes, the effects of their lipotransfection on cell growth, morphology and apoptotic death were examined in cultured Raji cells (Fig 3) . The number of living cells evaluated by the trypan blue exclusion test was clearly reduced at 48th h following lipotransfection (Fig 3a) . The typical apoptotic morphologies, that is a rapid cell shrinkage, followed by extensive blebbing leading to the formation of apoptotic bodies were only observed in the Raji cells lipotransfected with the modified active ARE-ribozyme (Fig 3b) . Furthermore, the number of cumulative apoptotic events scored in 48 h time course (Fig 3b) progressively increased following lipotransfection with the modified ARE-ribozyme, while both the inactive ARE-ribozyme and the inverted control elicited scarce effects on this parameter.
Discussion
The use of antisense DNA and ribozyme in gene therapy is ideally suited to treat these diseases that involve a specific transcript linked to disease etiology. In follicular non-Hodgkin's lymphoma and other tumors including lung, breast colorectal, prostate, renal and acute and chronic leukemias, there is evidence for an etiologic role of bcl-2 mRNA overexpression. The efficacy of antisense DNA and hammerhead ribozymes to inactivate gene expression in human cancers has been demonstrated by a number of groups: a good outcome was obtained by using antisense DNA targeting bcl-2 mRNA in human malignant glioma cells, 20 in malignant melanoma, 21 on human renal-cell carcinoma cells in vitro and in mice, 22 in hormone-refractory prostate cancer, 23 in acute myeloid leukemia cells 24 and non-Hodgkin's lymphoma. 7 As a result of their catalytic activity, ribozymes should be more effective than antisense DNA/RNaseH-based inhibition. In fact, many authors designed hammerhead ribozymes delivered by adenovirus vector in order to develop a gene therapy strategy to promote apoptosis in bcl-2 overexpressing cancer cells. [25] [26] [27] Synthetic ribozymes have been used for the inhibition of bcl-2 gene expression less than retroviral vector-derived ribozymes. A divalent hammerhead ribozyme was constructed by recombining two catalytic RNA domains 28 into an antisense segment of the coding region of human bcl-2 mRNA: transfection of this ribozyme reduced both bcl-2 mRNA and protein levels, and induced apoptosis in low-bcl-2-expressing prostate cancer cells but not in high-bcl-2-expressing cells. 28 On the contrary, to date, the only exogenously delivered synthetic ribozyme targeted to the bcl-2 mRNA open reading frame in chronic myelogenous leukemia cell lines was ineffective. 29 In fact, this ribozyme appears to interfere with cell death in myeloid cells, but is not able to reduce the number of malignant cells and to inhibit BCL-2 protein expression. 29 No data are available regarding the effects of this ribozyme on the levels of bcl-2 mRNA expression. The number of apoptotic events was scored, normalized to 100 initial living cell/optical field was recorded and summed for periods of 5 h. Each point was the mean 7 SEM of three independent experiments.
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In this study, we designed a bcl-2 ARE-targeting hammerhead ribozyme aimed at downregulating specifically bcl-2 expression either by directly cleaving bcl-2 ARE RNA or by interfering with bcl-2 ARE activity as a cis-acting element, or both.
Since the inhibition of gene expression depends on the identification of the target RNA regions that contain cleavage sites accessible for ribozyme-substrate complex formation, 2,15 the bcl-2 ARE-targeting ribozyme was siteselected by using a computer-folding program for RNA, and the target accessibility was confirmed by antisense probes ( Table 1 ). The bcl-2 ARE showed different accessible sites for ribozyme cleavage (GUC and AUC) with the AUC triplet at position 944 being the best (Table 1) . Our ARE-ribozyme has high catalytic efficiency as indicated by the ratio of k react /K M measured in in vitro trans-cleavage reaction under single-turnover conditions . Ribozymes are highly sensitive to ribonuclease and this precludes their administration through the culture medium unless they are chemically modified. In order to investigate the efficacy of the ARE-ribozyme to cleave the bcl-2 ARE RNA, and, consequently, the bcl-2 gene downregulation and commitment of Raji cells to apoptosis, we introduced 2 0 -aminouridines at positions U4 and U7, 2 0 -fluoropyrimidines and terminal phosphorothioates (Fig 1) . The stabilized ARE-ribozyme showed an increased half-life (data not shown) with approximately the same catalytic efficiency as the nonmodified AREribozyme. Investigation of the functional biological role of the ARE-modified ribozyme in cultured Burkitt lymphoma Raji cells confirmed the good activity and specificity of this ribozyme to cleave the cellular ARE-RNA. Cleavage of bcl-2 ARE interfered with the translation process downregulating the levels of the Bcl-2 antiapoptotic protein as showed by Western blot analysis. The inactive modified ARE-ribozyme did not appreciably affect bcl-2 mRNA as well as BCL-2 protein levels: inhibition of Bcl-2 protein expression decreased the lymphoma cells survival triggering apoptosis. Malignant lymphomas, in particular t(14;18) follicular lymphomas, are a growing cause of death from cancer in a large number of patients that fail to respond to irradiation, chemotherapy and immunotherapy. The successful clinical results obtained with some modified phosphorothioate antisense molecules against the BCL-2 protein 7, 30 would strengthen the rationale to plan clinical trials with ARE-modified ribozyme in patients with lymphoma, especially in those who are refractory to chemotherapy. In vitro and in vivo studies culminating in a human phase I study with bcl-2 antisense oligonucleotide to inhibit expression of bcl-2 have demonstrated good efficacy with low toxicity. 30 Tumor regression, clinical parameter and symptom improvement together with downregulation of target protein expression have also been achieved. 30 These results confirm a good chemotherapeutic drug. 30 Our results demonstrate that the synthetic, modified hammerhead ARE-ribozyme is able to commit bcl-2 overexpressing human lymphoma (Raji) cells to apoptosis, thus opening the possibility to develop a therapeutic agent to be applied with high specificity and efficiency in vivo. The inhibition of activity is because of enzymatic activity of the ribozyme as shown by comparing the effect to the antisense inactive ribozyme. The efficacy of our ribozyme results from specific site selection of the target triplet resulting in an accessible site that facilitates the binding, cleavage and dissociation of the ribozyme, thus enabling the catalytic activity of the ribozyme, the increased stability owing to chemical modifications, to the colocalization of the ribozyme and its target as well as to the biological relevance of the bcl-2 ARE RNA region, which, being a dynamic RNA-protein complex, offers more accessible sites to ribozyme binding. The ARE-RNA sequences are present in the 3 0 -UTR of genes that play an important role in different cancers and inflammation such as TNF-a, c-fos, k-ras and VEGF. Our comparative analysis of these ARE structures (data not shown) showed that the ARE secondary structure is maintained among these genes. Therefore, we propose that the ARE-ribozymes can serve as a universal and suitable tool to study the RNA/protein interactions to modulate the bcl-2 mRNA stability, 10, 31 and also to target the other genes implicated in cancer.
